產品屬性：
產品名稱 | Dapagliflozin-d5 |
規格 | 500 μg、1 mg |
貨號 | EY-01Y14313 |
Cas No.: 1204219-80-6
別名: N/A
化學名: N/A
分子式: C21H20ClD5O6
分子量: 413.9
溶解度: DMF: 30 mg/ml,DMSO: 30 mg/ml,Ethanol: 30 mg/ml
儲存條件: Store at 4°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
產品描述：
Dapagliflozin-d5 is intended for use as an internal standard for the quantification of dapagliflozin by GC- or LC-MS. Dapagliflozin is a first generation, selective sodium-glucose linked transporter (SGLT) inhibitor that blocks glucose transport with about 100-fold selectivity for SGLT2 (Ki = 6 nM; EC50 = 1.1 nM) over SGLT1 (Ki = 390 nM).1 After single oral doses ranging from 0.1 to 1.0 mg/kg, dapagliflozin increases urinary glucose excretion in both normal and diabetic rats, improves glucose tolerance in normal rats, and reduces hyperglycemia in Zucker diabetic fatty rats.2 Within two weeks of treating diabetic rats with 0.1 to 1.0 mg/kg dapagliflozin, fasting and fed glucose levels have been shown to be significantly lowered as a result of increased glucose utilization accompanied by reduced glucose production.
1.Chao, E.C., and Henry, R.R.SGLT2 inhibition - A novel strategy for diabetes treatmentNature Reviews.Drug Discovery9(7)551-559(2010)
2.Han, S., Hagan, D.L., Taylor, J.R., et al.Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic ratsDiabetes57(6)1723-1729(2008)
特別提醒公司產品僅供科研使用
